VWWMG
ACRV icon

Vermillion & White Wealth Management Group’s Acrivon Therapeutics ACRV Stock Holding History

Vermillion & White Wealth Management Group’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18,100
Closed -$43.6K – 72
2025
Q4 		$43.6K Buy
+18,100
New +$39.3K 0.02% 162

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vermillion & White Wealth Management Group's ACRV Position: Q1 2026 in Review

Vermillion & White Wealth Management Group sold out of Acrivon Therapeutics (ACRV) in Q1 2026, closing a stake of 18,100 shares — an estimated $43.6K sold.

Vermillion & White Wealth Management Group first reported a position in ACRV in Q4 2025 and held it in 1 quarter. The position peaked at $43.6K in Q4 2025. 44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

  • Vermillion & White Wealth Management Group reported no remaining Acrivon Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Vermillion & White Wealth Management Group sold 18,100 Acrivon Therapeutics shares in Q1 2026, an estimated $43.6K.
  • Vermillion & White Wealth Management Group first reported a position in Acrivon Therapeutics in Q4 2025 and held it in 1 quarter.
  • Vermillion & White Wealth Management Group's Acrivon Therapeutics position peaked at $43.6K in Q4 2025.
  • 44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on Vermillion & White Wealth Management Group's 13F filing for Q1 2026, filed 14 May 2026.